Combining cytochrome P-450 3A4 modulators and cyclosporine or everolimus in transplantation is successful

Figure 1 Gamma distribution curves with varying alpha and beta parameters.

Figure 2 Kidney allograft function estimated by plasma creatinine (A) and glomerular filtration rate estimated by mdrd formula (B). MMF: Mycophenolate mofetyl.

Figure 3 Graft survival un-censored (A) and graft survival censored (B) for patient death with a functioning graft. MMF: Mycophenolate mofetyl.

Figure 4 Cyclosporine daily dose (A), cyclosporine blood concentrations (B) and everolimus daily dose (C) during the first two years of follow-up. MMF: Mycophenolate mofetyl.

Figure 5 Everolimus blood concentrations during the first years of follow-up.

Figure 6 Correlation between plasma creatinine and blood cyclosporine concentration in the everolimus group (A) and mycophenolate mofetyl group (B).